Re/Max Holdings Inc
XBER:2RM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
R
|
Re/Max Holdings Inc
XBER:2RM
|
US |
|
P
|
PG&E Corp
DUS:PCG
|
US |
|
Judges Scientific PLC
F:IUF
|
UK |
|
T
|
Takeda Pharmaceutical Co Ltd
DUS:TKD
|
JP |
|
Fraport AG Frankfurt Airport Services Worldwide
F:FRA
|
DE |
|
Bluestone Jewellery and Lifestyle Ltd
NSE:BLUESTONE
|
IN |
|
Empress Royalty Corp
XTSX:EMPR
|
CA |
|
I
|
IDEXX Laboratories Inc
F:IX1
|
US |
|
O
|
Organon & Co
XBER:7XP
|
US |
Wall St Price Targets
2RM Price Targets Summary
Re/Max Holdings Inc
According to Wall Street analysts, the average 1-year price target for 2RM is 9.7 EUR with a low forecast of 9.61 EUR and a high forecast of 9.99 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 2RM's stock price target?
Price Target
9.7
EUR
According to Wall Street analysts, the average 1-year price target for 2RM is 9.7 EUR with a low forecast of 9.61 EUR and a high forecast of 9.99 EUR.
What is the Revenue forecast for Re/Max Holdings Inc?
Projected CAGR
3%
Over the last 14 years, the compound annual growth rate for Revenue has been 5%. The projected CAGR for the next 2 years is 3%.
What is the Operating Income forecast for Re/Max Holdings Inc?
Projected CAGR
13%
Over the last 14 years, the compound annual growth rate for Operating Income has been 1%. The projected CAGR for the next 2 years is 13%.
What is the Net Income forecast for Re/Max Holdings Inc?
Projected CAGR
95%
The compound annual growth rate for Net Income over the next 2 years is 95%.
